Advancements and Challenges of Cellular Immunotherapies:

Spotlight on CAR-T, TIL, and TCR Therapies

Executive Summary – Cellular immunotherapies, including CAR-T, TIL, and TCR therapies, have transformed modern medicine, offering personalized approaches to treat cancer and autoimmune diseases. CAR-T therapy has demonstrated exceptional efficacy in hematologic malignancies, though challenges such as side effects, manufacturing complexity, and limited solid tumor applicability persist. Emerging in vivo CAR-T therapies promise scalable and cost-effective solutions. TIL and TCR therapies provide new avenues for addressing solid tumors and intracellular targets, respectively. Advances in autoimmune disease treatments and neurodegenerative conditions, exemplified by systemic lupus erythematosus and multiple sclerosis, reveal the expanding potential of these therapies. This article explores the transformative strides and challenges in cellular immunotherapy, spotlighting the promise of in vivo techniques and innovative approaches reshaping this revolutionary field.

****

Introduction – Cellular immunotherapies have emerged as a cornerstone of modern medicine, revolutionizing how we treat complex diseases such as cancer and autoimmune disorders. These therapies leverage the body's immune system to target and eradicate diseased cells, paving the way for a new era in precision medicine. This document explores the journey of cellular immunotherapies, from their conceptual beginnings to their current transformative applications, highlighting the challenges and innovations shaping the field.

The Evolution of Cellular Immunotherapies – The concept of cellular immunotherapy dates back to the early 2010s, when the idea of genetically modifying a patient's own immune cells first began to gain traction. Companies like bluebird bio, Kite Pharma, and Juno Therapeutics pioneered the development of CAR-T cell therapies, which involve engineering T cells to recognize and destroy cancer cells. Kite, acquired by Gilead Sciences in August 2017 for approximately $12 billion, and Juno, acquired by Celgene in January 2018 for $9 billion before Celgene itself was acquired by Bristol Myers Squibb in November 2019 for $74 billion, represent key milestones in the evolution of the cellular immunotherapy landscape.

Other significant milestones include the FDA approval of Novartis' Kymriah (tisagenlecleucel) in 2017, marking the first CAR-T therapy approved for pediatric and young adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). The same year, Kite's Yescarta (axicabtagene ciloleucel) became the second FDA-approved CAR-T therapy, targeting relapsed or refractory large B-cell lymphoma. The introduction of off-the-shelf CAR-T therapies by companies like Allogene Therapeutics further revolutionized the field by addressing scalability and accessibility challenges.

Additional advancements include the development of dual-targeting CAR-T therapies (e.g., those targeting CD19 and CD22 simultaneously), the approval of Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel) in 2021, and the emergence of bispecific and CRISPR-edited CAR-T therapies, which broadened the scope of potential applications. In 2023, the FDA's approval of Iovance's TIL therapy for melanoma underscored the promise of non-CAR-T cellular therapies for solid tumors. The advent of in vivo CAR-T therapies, designed to modify T cells directly within the patient, marks a revolutionary shift, simplifying and accelerating treatment delivery.

Despite early setbacks, including severe side effects and patient deaths during trials, advances in understanding immune responses and cytokine regulation paved the way for safer and more effective therapies. By the mid-2010s, these treatments were achieving remarkable response rates in hematologic cancers, ushering in a new era of precision medicine [1, 3]. Challenges included controlling cytokine release syndrome and neurotoxicity, which were mitigated through IL-6 inhibitors and improved monitoring strategies [3, 4]. Moreover, the shift toward off-the-shelf and in vivo engineering approaches has expanded accessibility and reduced production times [5, 6]. Today, cellular immunotherapies represent a rapidly evolving field with transformative potential in oncology, autoimmune diseases, and beyond.

CAR-T Therapy: Transforming Hematologic Cancer Care – CAR-T therapy involves engineering a patient's T cells to express receptors that recognize and eliminate cancer cells. This approach has shown remarkable success in treating hematologic malignancies like B-cell lymphomas and ALL, with response rates exceeding 80% in some studies [1, 2]. Yet, CAR-T therapy is not without its limitations:

1. **Side Effects**: Cytokine release syndrome (CRS) and neurotoxicity remain significant concerns, requiring intensive monitoring and management [1, 3].
2. **Limited Efficacy in Solid Tumors**: The immunosuppressive microenvironment and heterogeneity of antigens in solid tumors impede CAR-T's effectiveness beyond hematologic cancers [4].
3. **Relapse and Durability**: Many patients experience relapse within months, underscoring the need for strategies to enhance CAR-T cell persistence [5].
4. **Manufacturing Challenges**: The ex vivo manufacturing process is time-consuming and expensive, limiting accessibility. Emerging in vivo CAR-T generation strategies—using viral vectors or nanoparticles to engineer T cells within the patient—offer a promising alternative, potentially reducing costs and treatment timelines [6].

TIL Therapy: A Solution for Solid Tumors – Tumor-Infiltrating Lymphocyte (TIL) therapy isolates and expands lymphocytes from a patient's tumor, leveraging their natural tumor-specificity. This approach has shown promise in treating melanoma, with recent FDA approval highlighting its potential.

- **Strengths**: TIL therapy can target a broad spectrum of tumor antigens, making it effective against heterogeneous tumors [4].
- **Challenges**: The therapy demands extensive lab work, and patients must undergo lymphodepleting chemotherapy, which can lead to complications. Additionally, scaling production for widespread use remains an issue [6].

TCR Therapy: Targeting Intracellular Antigens – TCR therapies involve engineering T cells to recognize tumor-specific antigens presented on the cell surface by human leukocyte antigens (HLAs). These therapies expand the scope of cellular immunotherapy to include intracellular targets, such as those associated with synovial sarcoma and certain melanomas.

- **Advantages**: TCR therapies can target a wider range of tumor antigens, including non-surface proteins.
- **Barriers**: Their efficacy is dependent on HLA compatibility, limiting universal application. Furthermore, overcoming immune escape mechanisms remains critical [4].

Cellular Immunotherapies for Autoimmune Diseases – Recent studies have extended CAR-T applications to autoimmune diseases, such as systemic lupus erythematosus (SLE). Anti-CD19 CAR-T therapy has demonstrated the ability to deplete autoreactive B cells, leading to sustained remission

and improved clinical outcomes in treatment-resistant lupus patients. This breakthrough underscores the potential of cellular immunotherapy beyond oncology [7].

CAR-T Therapy for Neurodegenerative Diseases: A New Frontier – The initiation of CAR-T therapy trials in the U.S. for multiple sclerosis (MS) marks a pivotal moment in the development of therapies for neurodegenerative diseases, offering new hope for patients with limited treatment options. The use of CAR-T cell therapy, specifically KYV-101, shows promise in altering the treatment paradigm for MS by readjusting the immune system. This groundbreaking approach with KYV-101 could revolutionize MS treatment and potentially lead to life-changing outcomes [9].

In Vivo Cell Therapy: A Breakthrough Transformation – The field of cell therapy is undergoing a breakthrough transformation. In vivo cell therapy (an innovative approach that modifies patient cells directly within the body) is making strides that could reshape how we tackle complex diseases like cancer. This approach merges the benefits of both autologous and allogeneic therapies, aiming to overcome the challenges of traditional cell therapies with improvements in scalability, reduced costs, and enhanced safety. Imagine the power of harnessing the body's own cells to fight disease more effectively, with fewer side effects.

Pioneers like Interius BioTherapeutics, Umoja Biopharma, and Kelonia Therapeutics are already showing promising early results in cancer treatment [10]. This new wave holds the potential to minimize harmful side effects like cytokine release syndrome, paving the way for more robust and tolerable treatments for patients.

Overarching Challenges and Future Directions

1. **Cost and Accessibility**: The high cost of manufacturing and administering these therapies limits their availability. Development of off-the-shelf allogeneic T-cell therapies could democratize access.
2. **Safety Profiles**: Managing severe side effects, such as CRS and neurotoxicity, is paramount for wider adoption.
3. **Solid Tumor Barriers**: Innovations in CAR designs, such as incorporating co-stimulatory domains and developing bispecific CARs, are being explored to address antigen heterogeneity and immune suppression in solid tumors [8].
4. **Regulatory and Manufacturing Hurdles**: Streamlining approval processes and scaling manufacturing capabilities are critical for the global rollout of these therapies [6].

Addressing these challenges requires a multi-faceted approach, including the integration of advanced manufacturing technologies, collaborative regulatory frameworks, and innovative designs like universal CAR-T cells, which promise to improve durability, reduce costs, and enhance patient outcomes globally. Development of off-the-shelf allogeneic T-cell therapies could democratize access.

Lessons Learned from Autolus' CAR-T Therapies – The recent U.S. FDA approval of Autolus' CD19-directed genetically modified autologous T-cell immunotherapy, **Aucatzyl** (obecabtagene autoleucel), for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) marks a significant milestone. Aucatzyl not only offers a breakthrough in efficacy and safety but also becomes the first CAR-T therapy approved without the requirement for a Risk Evaluation and Mitigation Strategy (REMS) program, highlighting its favorable safety profile in mitigating risks such as CRS and other toxicities.

Building on its innovative design, Aucatzyl incorporates several key features that exemplify the next generation of CAR-T therapies, addressing critical safety and efficacy challenges in the field:

- **Rapid Onset Mechanisms**: Optimized CAR constructs enable quicker yet regulated activation, minimizing the time to therapeutic response while avoiding excessive inflammatory cascades.
- **Dual-Signaling CARs**: These require engagement of two antigens for activation, enhancing specificity and reducing off-target effects.
- **Inclusion of Safety Switches**: Suicide switches integrated into the therapy allow clinicians to halt treatment in the event of severe toxicity, ensuring patient safety.
- **Optimized Dosing Strategies**: Adjusting the initial infusion dose based on patient response minimizes CRS risk without compromising efficacy.

These advancements illustrate the potential for CAR-T therapies to achieve greater precision and safety, setting new benchmarks for the field.

Conclusion – Cellular immunotherapies have undeniably revolutionized the treatment landscape for cancers and autoimmune diseases. While CAR-T therapies have paved the way, advancements in TIL and TCR therapies offer hope for addressing the challenges of solid tumors. Continued innovation, from in vivo CAR-T engineering to overcoming immunosuppressive barriers, is essential to unlocking the full potential of these groundbreaking treatments. With sustained research and investment, cellular immunotherapies could transform the paradigm of personalized medicine.

****

References

1. Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. *Blood Cancer Journal.* 2021;11(4):69.
2. Madduri D, Berdeja JG, Usmani SZ, et al. CARTITUDE-1: phase 1b/2 study of ciltacabtagene autoleucel in relapsed/refractory multiple myeloma. *Blood.* 2020;136(Supplement 1):22–25.
3. Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. *Nature Reviews Clinical Oncology.* 2020;17(3):147–167.
4. Fan M, Liu H, Yan H, et al. A CAR T-inspiring platform based on antibody-engineered exosomes from antigen-feeding dendritic cells for precise solid tumor therapy. *Biomaterials.* 2022;282:121424.
5. Agarwal S, Weidner T, Thalheimer FB, Buchholz CJ. In vivo generated human CAR T cells eradicate tumor cells. *OncoImmunology.* 2019;8(12):e1671761.
6. Michels A, Ho N, Buchholz CJ. Precision medicine: in vivo CAR therapy as a showcase for receptor-targeted vector platforms. *Molecular Therapy.* 2022;30(7):2401–2415.
7. Schett G, McInnes IB, Neurath MF. CAR T cell therapy in autoimmune diseases: state of the art and future perspectives. *Nature Reviews Immunology.* 2022;22(12):704–712.
8. Harrison AJ, Du X, von Scheidt B, Kershaw MH, Slaney CY. Enhancing co-stimulation of CAR T cells to improve treatment outcomes in solid cancers. *Immunotherapy Advances.* 2021;1(1):ltab016.
9. Mullard A. CAR-T therapy for multiple sclerosis enters US trials for first time. *Nature*. 2024 Feb 22. doi: 10.1038/d41586-024-00470-5.
10. Viva la vivo: Next-generation cell therapy fast approaching. *PharmaPhorum.* Available from: https://pharmaphorum.com/rd/viva-vivo-next-generation-cell-therapy-fast-approaching.

Author: **Dr. Jean Chatellier, PhD**
Partner, EVP & Managing Director
KYBORA
Email: jean@kybora.com **|** Cell/WhatsApp: +33 609 102 105